Students of Australia’s first medicinal cannabis course at Deakin University will learn everything there is to know about marijuana, but don’t expect rolling a joint to be featured on the 8 week syllabus.
Dr Henry Pinskier, chair of a new Australian business launching the program called Cann10 Australia, said there was still a “distinct lack of awareness” within Australia’s health sector about the laws governing the use of medicinal cannabis (it varies widely between states), methods of cultivation and manufacturing, and how medical marijuana can be prescribed to approved patients.
This is despite reports of a growing number of patients asking for medicinal cannabis prescriptions to treat chronic pain and terminal illness.
“There is an overall lack of knowledge, training and education in this space, while there is increasing community interest, government activity and slowly increasing amounts of research across the sector,” he said.
The 8 week course offered by Deakin University will examine the “whole continuum of medicinal cannabis,” he said, from the science behind the product, the outcomes of clinical trials, and growing commercial opportunities in the global billion-dollar industry.
Cann10 Australia will be available to students and professionals in the fields of medicine, science, agriculture and commerce, who will learn from the leading cannabis industry figures including Peter Crock, the chief executive of Cann Group, Australia’s first company to receive a licence to cultivate medicinal cannabis.
Medicinal cannabis was made legal in Victoria early last year, and is already being used in trials involving children with epilepsy.
New federal government changes have loosened importation laws and boosted the local supply of medical grade marijuana, giving patients faster access to the product.
Read the full article on theage.com.au